title: Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
abstract: BACKGROUND
  This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients.
  
  
  METHODS
  From June 1996 to June 2001, 228 stage IB-IIIB gastric cancer patients were enrolled. All patients received a total or subtotal gastrectomy with at least a D1 lymphoadenectomy and were randomly assigned to receive surgery alone or surgery followed by chemotherapy.
  
  
  RESULTS
  A total number of 630 cycles was delivered with a median number of 5. With a median follow-up of 60 months, the 5-year overall survival (OS) was 48% in the treatment arm and 43.5% in the control arm [hazard ratio (HR) 0.91; 95% confidence interval (CI) 0.69-1.21; P = 0.610); the 5-year disease-free survival (DFS) was 44% in the treatment arm and 39% in the control arm (HR 0.88; 95% CI 0.78-0.91; P = 0.305). In node-positive patients, the 5-year OS was 41% in the treatment arm and 34% in the control arm (HR 0.84; 95% CI 0.69-1.01; P = 0.068), while the 5-year DFS was 39% in the treatment arm and 31% in the control arm (HR 0.88; 95% CI 0.78-0.91; P = 0.051). The most common grade 3-4 toxic effects according to World Health Organization criteria were hematological and gastrointestinal.
  
  
  CONCLUSIONS
  In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone.
authors.affiliation: Division of Medical Oncology, Second University, Napoli, Italy. fernandodevita@yahoo.it
authors.forename: F
authors.initials: F
authors.lastname: De Vita
authors.forename: F
authors.initials: F
authors.lastname: Giuliani
authors.forename: M
authors.initials: M
authors.lastname: Orditura
authors.forename: E
authors.initials: E
authors.lastname: Maiello
authors.forename: G
authors.initials: G
authors.lastname: Galizia
authors.forename: N
authors.initials: N
authors.lastname: Di Martino
authors.forename: F
authors.initials: F
authors.lastname: Montemurro
authors.forename: G
authors.initials: G
authors.lastname: Cartenì
authors.forename: L
authors.initials: L
authors.lastname: Manzione
authors.forename: S
authors.initials: S
authors.lastname: Romito
authors.forename: V
authors.initials: V
authors.lastname: Gebbia
authors.forename: F
authors.initials: F
authors.lastname: Ciardiello
authors.forename: G
authors.initials: G
authors.lastname: Catalano
authors.forename: G
authors.initials: G
authors.lastname: Colucci
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
chemical_list: D015251:Epirubicin; D005047:Etoposide; D002955:Leucovorin; D005472:Fluorouracil